Effects of Non-invasive Ventilation in Patients Undergoing Heart Surgery

Cardiac Surgical Procedures Clinical Trial

Official title:

Effects of Non-invasive Ventilation With Different Modalities in Patients Undergoing Heart Surgery: a Randomized Controlled Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05966337
• Other study ID #: ERAECR12023
• Secondary ID: 65600722.1.0000.
• Status: Recruiting
• Phase: N/A
• Start date: August 2023
• Est. completion date: February 2024

Study information

• Verified date: July 2023
• Source: Universidade Federal do Rio Grande do Norte
• Contact: Eder R Araújo, doctoral
• Phone: +5583988998813
• Email: eder.rodrigues.araujo[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this randomized controlled clinical trial is to compare effects of non-invasive ventilation with different modalities (notably CPAP and BIPAP) in patients undergoing heart surgery. The main question[s] it aims to answer are:

• Which NIV ventilation mode is most effective in cardiac surgery patients?

• Is there a big difference between conventional physiotherapy treatment and the use of NIV in these patients? Participants will be submited in the intervention will initially take place in the specific ward that receives patients in the postoperative period of cardiac surgery. Participants will be recruited after the patient is hospitalized the day before the surgery, during which time he will undergo a preoperative evaluation based on the study criteria. On that first day, the evaluation will consist of anamnesis and physical examination, focusing on the history of cardiac disorders, followed by measurements inherent to the protocol. Manovacuometry, chest X-ray, quality of life questionnaire, walk test and spirometry. The evaluation can be carried out in two stages, if there are other demands for the patient during his hospitalization.

Researchers will compare three groups: 1 - cpap group - CPAP + usual physical therapy care, 2

• Bipap group - BIPAP + usual physical therapy care and 3 - Control - usual physical therapy care), in the 1:1 allocation ratio and superiority. to see if the effects of non-invasive ventilation with different modalities in patients undergoing cardiac surgery demonstrates some superior way in clinical practice. The observed outcomes will be: evaluation between NIV modalities, spirometry, lung capacity and vital signs. Secondary outcomes included are degree of satisfaction with the global perception of change scale, and MIF - functional independence measure and blood gas parameters.

Description:

The study protocol was conducted following the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist. This is a single-center, randomized, controlled, double-blind clinical trial, in which participants and outcome evaluators were blinded. The study will be submitted to the ethics committee of the State University of Paraíba (UEPB) and carried out in accordance with the Declaration of Helsinki. All participants must provide written informed consent prior to participation, and the study will be registered on the CLINICALTRIALS platform. All participants must provide written informed consent prior to participation. Participants will be divided into three groups (cpap group - CPAP + usual physical therapy care, bipap group - BIPAP + usual physical therapy care and control group - usual physical therapy care), in a 1:1 allocation ratio and superiority.

The project will be carried out at Hospital João XXIII in the city of Campina Grande, Paraíba, Brazil. It is a private hospital affiliated with the SUS network, a reference in cardiology and especially in cardiac surgery for a good part of the state and surrounding states. It presents in its weekly program an average of 8 cardiac surgeries. The evaluation and intervention will take place in the ICU and ward.

Post-randomization exclusion criteria: In case of undertaking any treatment in the hospital environment that contraindicates participation in the study (pacemaker implantation, pneumothorax requiring chest drainage, for example), death or other decompensations not related to the research and return to the ICU .

Criteria for non-adherence to the intervention: Patient who does not perform 3 or more sessions in a row, who withdrew from participating in the study and who has some cardiac arrhythmia (atrial fibrillation, bradycardia) for two sessions even after medication used to contain and pause for rest.

Non-retention criteria: Patient who does not perform one of the reassessments. Professional eligibility criteria: Hospital staff physiotherapists and physiotherapy students with previous training in the research protocol.

Procedures for Conducting the Research The purpose of this project is to carry out a randomized clinical trial and verify the effectiveness of NIV compared to conventional physiotherapy in terms of the rate of pulmonary complications in patients undergoing cardiac surgery in a chosen hospital in the city of Campina Grande, Paraíba.

Thus, there will be a partnership with the Núcleo de Tecnologia Estratégicas em Saúde (NUTES) of the State University of Paraíba (UEPB) through the biomedical computing laboratory for the development of research aimed at the remote monitoring of health data through smartwatches and other devices that comply with international standardization norms for interoperability between health technologies. NUTES already collaborates with UFRN in several scientific and technological cooperation researches, so that the co-supervisor of the project, Prof Paulo Eduardo Barbosa made the strategic partnership possible, according to the attached document. NUTES' participation in this project will take place through the feasibility of remote monitoring technology via Smartwatch and the introduction of data collected on a specific platform.

For a better understanding and operationalization of the research, it was divided into 5 phases.

1. st Phase: Documentary Survey and Consent At first, there was initial contact with the aforementioned hospital institution for consent to the research. At the same time, a documentary and systematic study on the subject was instituted, in order to base the research and identify possible indices and/or parameters that would add to the research in order to make it viable and absolutely realistic.

2. nd Phase: Search and profile of NIV and Smartwatch devices Non-invasive ventilation (NIV) will be performed both in the ICU environment and in the ward for the intervention group. A BIPAP will be made available and a CPAP for the respective groups. The interface chosen will be the nasal mask, aiming at greater patient comfort. Thus, we will choose properly calibrated NIV devices on the market that provide better adaptation to patients.

All the main information about users can be entered into the platform, such as gender, age, other illnesses, use of medication, and some special situations that can be verified in practice, in addition to information that may come from the monitoring carried out by the smartwatch on patients in the moment of data collection during NIV application. Thus, data from the patient's medical record will also be used. A large volume of data can be entered into the platform and used to generate a profile of cardiac patients selected for the survey. The smartwatch used will be from the Garmin brand and available for capturing Sao2 and VO2.

The main functionalities of the Dashboard comprise the visualization of the data of the surgical patients submitted to NIV in the initial screen in a computer, being able to apply filters according to the interest of the researcher.

3. rd Phase: Technical Study and applied tests

This project is interested in three major aspects: the use of non-invasive ventilation in heart patients undergoing cardiac surgery; the automation of data collection using the smartwatch, making it practical, simple, accessible technology in order to become a predictor of safe discharge for these patients; finally, a survey of a large volume of data (verified in the analysis profile of the patients) that can generate subsidies for carrying out research and contribute to the increase of studies in the area of cardiopulmonary physiotherapy on technological bases.

4. th Phase: Pilot Study - Practice After that, the surgeries will begin and the collection will consist of 6 patients, thus defining the beginning of the pilot study. Upon being notified of the weekly surgical schedule, the researcher in charge will randomize the patients. This register will contain the complete identification of the patient, type of surgery to which he will be submitted and the pathology.

Thus, as the patients leave the surgical center and go to the ICU, they will follow the protocol so that the treatment due to the group to which the patient is allocated on the day after the surgery begins.

It should be noted that the pilot study should only be started after approval by CEP.

After completion of the pilot study, there will be an evaluation of the entire protocol so that possible flaws can be corrected before definitive collection.

5. th Phase: Data collection It will consist of collecting data from patients in the post-randomization intervention and allocation of patients to a group, following the procedures of the protocol.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 62
• Est. completion date: February 2024
• Est. primary completion date: February 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria: Patients undergoing cardiac surgery

• aged over 18 years

• stable from the hemodynamic point of view (controlled blood pressure, normocardic

• conscious and oriented and cooperative4

• without medical restrictions for carrying out the treatment

Exclusion Criteria:

• Presence of uncontrolled cardiac arrhythmias (Examples: total atrioventricular block, type 2 2nd degree atrioventricular block, atrial fibrillation, sustained ventricular tachycardia)

• previous neuromuscular disease

• labyrinthitis and some orthopedic/skeletal muscle restriction.

• Unstable angina, stage 3 SAH (SBP = 180 mmHg and/or DBP = 110 mmHg at rest), HR > 120 bpm at rest, systemic arterial hypotension with clinical repercussions (SBP = 90 mmHg and/or DBP = 60 mmHg),(),

• aortic dissection.

Related Conditions & MeSH terms

• Cardiac Surgical Procedures
• Continuous Positive Airway Pressure

Intervention

Procedure:
• CPAP
Use of non-invasive ventilation in patients in group 2 with CPAP.
• BIPAP
Use of non-invasive ventilation in patients in group 3 with BIPAP.
• Usual care in phisicaltherapy
Patients undergoing usual physiotherapy treatment, consisting of a kinesiotherapy protocol

Locations

Country	Name	City	State
Brazil	Hospital João XXIII	Campina Grande	PB

Sponsors (2)

Lead Sponsor	Collaborator
Universidade Federal do Rio Grande do Norte	Universidade Estadual da Paraiba

Country where clinical trial is conducted

Brazil, 

References & Publications (14)

8. Vieira WO, Barbosa LK, Bezerra AS, et al. Test timed up and go and its correlation with age and functional exercise capacity in asymptomatic women. Fisioterapia em Movimento. 2017;30(3):463-471. doi:10.1590/1980-5918.030.003.AO04.

American Thoracic Society/European Respiratory Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med. 2002 Aug 15;166(4):518-624. doi: 10.1164/rccm.166.4.518. No abstract available. — View Citation

Bai C, Chotirmall SH, Rello J, Alba GA, Ginns LC, Krishnan JA, Rogers R, Bendstrup E, Burgel PR, Chalmers JD, Chua A, Crothers KA, Duggal A, Kim YW, Laffey JG, Luna CM, Niederman MS, Raghu G, Ramirez JA, Riera J, Roca O, Tamae-Kakazu M, Torres A, Watkins RR, Barrecheguren M, Belliato M, Chami HA, Chen R, Cortes-Puentes GA, Delacruz C, Hayes MM, Heunks LMA, Holets SR, Hough CL, Jagpal S, Jeon K, Johkoh T, Lee MM, Liebler J, McElvaney GN, Moskowitz A, Oeckler RA, Ojanguren I, O'Regan A, Pletz MW, Rhee CK, Schultz MJ, Storti E, Strange C, Thomson CC, Torriani FJ, Wang X, Wuyts W, Xu T, Yang D, Zhang Z, Wilson KC. Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). Eur Respir Rev. 2020 Oct 5;29(157):200287. doi: 10.1183/16000617.0287-2020. Print 2020 Sep 30. — View Citation

Behlouli H, Feldman DE, Ducharme A, Frenette M, Giannetti N, Grondin F, Michel C, Sheppard R, Pilote L. Identifying relative cut-off scores with neural networks for interpretation of the Minnesota Living with Heart Failure questionnaire. Annu Int Conf IEEE Eng Med Biol Soc. 2009;2009:6242-6. doi: 10.1109/IEMBS.2009.5334659. — View Citation

Bretan O, Silva Junior JE, Ribeiro OR, Corrente JE. Risk of falling among elderly persons living in the community: assessment by the Timed up and go test. Braz J Otorhinolaryngol. 2013 Jan-Feb;79(1):18-21. doi: 10.5935/1808-8694.20130004. — View Citation

Carvalho VO, Guimaraes GV, Carrara D, Bacal F, Bocchi EA. Validation of the Portuguese version of the Minnesota Living with Heart Failure Questionnaire. Arq Bras Cardiol. 2009 Jul;93(1):39-44. doi: 10.1590/s0066-782x2009000700008. English, Portuguese, Spanish. — View Citation

Castro D, Patil SM, Keenaghan M. Arterial Blood Gas. 2022 Sep 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK536919/ — View Citation

Chua HR, Schneider A, Bellomo R. Bicarbonate in diabetic ketoacidosis - a systematic review. Ann Intensive Care. 2011 Jul 6;1(1):23. doi: 10.1186/2110-5820-1-23. — View Citation

Dos Santos TD, Pereira SN, Portela LOC, Cardoso DM, Lago PD, Dos Santos Guarda N, Moresco RN, Pereira MB, de Albuquerque IM. Moderate-to-high intensity inspiratory muscle training improves the effects of combined training on exercise capacity in patients after coronary artery bypass graft surgery: A randomized clinical trial. Int J Cardiol. 2019 Mar 15;279:40-46. doi: 10.1016/j.ijcard.2018.12.013. Epub 2018 Dec 10. — View Citation

Du H, Newton PJ, Salamonson Y, Carrieri-Kohlman VL, Davidson PM. A review of the six-minute walk test: its implication as a self-administered assessment tool. Eur J Cardiovasc Nurs. 2009 Mar;8(1):2-8. doi: 10.1016/j.ejcnurse.2008.07.001. Epub 2008 Aug 9. — View Citation

Hossen A, Jaju D, Al-Abri M, Al-Sabti H, Mukaddirov M, Hassan M, Al-Hashmi K. Investigation of heart rate variability of patients undergoing coronary artery bypass grafting (CABG). Technol Health Care. 2017;25(2):197-210. doi: 10.3233/THC-161260. — View Citation

Rodriguez P, Lellouche F, Aboab J, Buisson CB, Brochard L. Transcutaneous arterial carbon dioxide pressure monitoring in critically ill adult patients. Intensive Care Med. 2006 Feb;32(2):309-312. doi: 10.1007/s00134-005-0006-4. Epub 2006 Jan 31. — View Citation

Shakouri SK, Salekzamani Y, Taghizadieh A, Sabbagh-Jadid H, Soleymani J, Sahebi L, Sahebi R. Effect of respiratory rehabilitation before open cardiac surgery on respiratory function: a randomized clinical trial. J Cardiovasc Thorac Res. 2015;7(1):13-7. doi: 10.15171/jcvtr.2015.03. Epub 2015 Mar 29. — View Citation

Valkenet K, de Heer F, Backx FJ, Trappenburg JC, Hulzebos EH, Kwant S, van Herwerden LA, van de Port IG. Effect of inspiratory muscle training before cardiac surgery in routine care. Phys Ther. 2013 May;93(5):611-9. doi: 10.2522/ptj.20110475. Epub 2013 Jan 3. — View Citation

* Note: There are 14 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Duration of Cardiopulmonary Bypass	The duration of cardiopulmonary bypass during the cardiac surgery. • Unit of Measure: minutes	Day 1
Other	Type of Surgery	The specific type of cardiac surgery performed. • Unit of Measure: N/A (Categorical Variable)	Day 1
Other	Personal History	Relevant information about the patient's personal medical history. • Unit of Measure: N/A (Categorical Variable)	Day 1
Other	Preoperative Ejection Fraction	The percentage of preoperative cardiac ejection fraction.• Unit of Measure: percentage (%)	Day 1
Other	Previous Respiratory Complications	Indication of the presence or absence of previous respiratory complications. • Unit of Measure: N/A (Categorical Variable)	Day 1
Other	Body Mass Index (BMI)	The patient's body mass index, calculated as weight (in kg) divided by the square of height (in meters). Unit of Measure: N/A (Calculated from weight and height)	Day 1
Other	Gender	The patient's gender (male or female). Unit of Measure: N/A (Categorical Variable)	Day 1
Other	Age	The patient's age in years	Day 1
Primary	Pulmonary function	All participants will undergo an evaluation by a CONTEC model spirometer (SPB80b, CHINA) to verify lung volumes and capacities. At least three tests will be performed, with a variation of less than 5% and the highest value obtained in one of the tests will be compared with the predicted values of pulmonary function parameters for the Brazilian population. FEV1 and FVC will be assessed. The predicted values will be calculated using the reference values (PEREIRA et al., 2007).	Day 1 and day 5
Primary	Length of hospital stay	Absolute number of days of hospitalization up to 2 weeks after the date of randomization.	The length of hospital stay will be assessed and reported as the number of days from admission to discharge, measured up to 2 weeks after the date of randomization.
Primary	Presence of lung complications	assessment of the occurrence or absence of any complications related to the lungs during the hospitalization period.cause, whichever occurs first, measured up to 2 weeks	From the date of randomization to the date of the first documented progression or the date of death from any cause, whichever occurs first, measured up to 2 weeks after the date of hospital discharge.
Secondary	Score of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in Portuguese version	The Portuguese version of the MLHFQ will be used to assess the patient's quality of life. The questionnaire provides a final score as a metric, and the change in score over the treatment period will be evaluated. The MLHFQ score is a measure of health-related quality of life in patients with heart failure. The higher the score, the greater the negative impact of heart failure on the patient's quality of life. A score of 0 indicates that the patient has no limitations or problems related to heart failure, while a score of 105 indicates a maximum limitation or problem in all areas assessed by the questionnaire.	Day 1 and Day 5
Secondary	Funcional capacity	The TUG test will be performed to assess functional capacity. The patient will start from a sitting position, walk quickly for 3 meters, turn 180 degrees, and return to the chair. The time taken, measured from standing up to completely leaning the trunk against the chair, will be recorded. Time values below 10 seconds indicate maximum functionality, 10 to 19 seconds indicate functional independence, 20 seconds and above indicate some functional limitation, and 30 seconds and above indicate significant functional limitation.	Day 1 and Day 5
Secondary	The global perception of change scale	The GPCS is a self-report tool that assesses an individual's perception of change in a specific domain. It uses Likert-scale items ranging from "a very great deal worse/less" to "a very great deal better/more" to capture subjective information about perceived change.	Day 1 and Day 5
Secondary	The functional independence measure (MIF)	The MIF questionnaire will be administered preoperatively and on the sixth day to assess functional independence.	Day 1 and Day 5
Secondary	pO2 (partial pressure of oxygen)	Partial pressure of oxygen (PO2) is a key physiological parameter that measures the pressure exerted solely by oxygen molecules in a mixture of gases, such as air or blood. It is an important indicator of the oxygen-carrying capacity and oxygen exchange efficiency in the respiratory system (ROCA et al. 2020). PO2 will be measured in millimeters of mercury (mmHg) (BAI, et al. 2020)	Days 1 and 2.
Secondary	pCO2 (partial pressure of carbon dioxide)	Partial pressure of carbon dioxide (pCO2) is a fundamental physiological parameter that measures the pressure exerted solely by carbon dioxide molecules in a mixture of gases, such as air or blood. It plays a crucial role in the regulation of acid-base balance and respiratory function.; The unit of measurement for pCO2 will be expressed in millimeters of mercury (mmHg).(RODRIGUEZ, 2006)	Days 1 and 2.
Secondary	HCO3 (bicarbonate)	Bicarbonate (HCO3) is an important physiological parameter that measures the concentration of bicarbonate ions in the blood. It is a vital component of the body's acid-base balance and plays a crucial role in maintaining the pH of the blood within a normal range.; The unit of measurement for bicarbonate will be expressed in milliequivalents per liter (mEq/L) (CHUA, 2011).	Days 1 and 2.
Secondary	Arterial Oxygen Saturation (SaO2)	Arterial Oxygen Saturation (SaO2) is a critical physiological parameter that measures the percentage of hemoglobin in arterial blood that is bound with oxygen. It reflects the efficiency of oxygen transport from the lungs to the body's tissues.; The unit of measurement for SaO2 is typically expressed as a percentage (%). (CASTRO, et al, 2022)	Days 1 and 2.
Secondary	Base Excess (BE)	Base Excess (BE) is a significant physiological parameter that measures the amount of excess or deficit of base (bicarbonate) in the blood, indicating the body's acid-base balance. It quantifies the deviation of the blood's buffering capacity from the normal range, which helps in assessing the metabolic component of acid-base disturbances.; The unit of measurement for Base Excess will be expressed in milliequivalents per liter (mEq/L) (CASTRO, et al, 2022)	Days 1 and 2.